ENvue Medical annual gross margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
ENvue Medical's gross margin was 5.99% for fiscal 2025.
View full ENvue Medical company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 5.99% | −52.96 pp |
| 2024 | 2024-12-31 | 58.95% | −8.37 pp |
| 2023 | 2023-12-31 | 67.32% | +45.12 pp |
| 2022 | 2022-12-31 | 22.21% | −23.22 pp |
| 2021 | 2021-12-31 | 45.43% | +11.08 pp |
| 2020 | 2020-12-31 | 34.35% | −18.67 pp |
| 2019 | 2019-12-31 | 53.02% | +2.70 pp |
| 2018 | 2018-12-31 | 50.31% | −12.87 pp |
| 2017 | 2017-12-31 | 63.18% | +1.61 pp |
| 2016 | 2016-12-31 | 61.57% | −5.09 pp |
| 2015 | 2015-12-31 | 66.67% | +12.48 pp |
| 2014 | 2014-12-31 | 54.19% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −111.30% | −104.21 pp |
| Q1 2026 | 2026-03-31 | −8.42% | −44.42 pp |
| Q4 2025 | 2025-12-31 | −118.59% | −182.33 pp |
| Q3 2025 | 2025-09-30 | 26.18% | −9.20 pp |
| Q2 2025 | 2025-06-30 | −7.09% | −59.47 pp |
| Q1 2025 | 2025-03-31 | 36.00% | −36.10 pp |
| Q4 2024 | 2024-12-31 | 63.74% | +1.12 pp |
| Q3 2024 | 2024-09-30 | 35.37% | −40.83 pp |
| Q2 2024 | 2024-06-30 | 52.39% | −21.08 pp |
| Q1 2024 | 2024-03-31 | 72.10% | +5.71 pp |
| Q4 2023 | 2023-12-31 | 62.62% | −19.86 pp |
| Q3 2023 | 2023-09-30 | 76.20% | +18.26 pp |
| Q2 2023 | 2023-06-30 | 73.47% | +34.50 pp |
| Q1 2023 | 2023-03-31 | 66.38% | +33.22 pp |
| Q3 2022 | 2022-09-30 | 82.47% | +36.78 pp |
| Q2 2022 | 2022-06-30 | 57.94% | −7.47 pp |
| Q1 2022 | 2022-03-31 | 38.97% | −35.79 pp |
| Q4 2021 | 2021-12-31 | 33.16% | +4.27 pp |
| Q3 2021 | 2021-09-30 | 45.69% | −20.31 pp |
| Q2 2021 | 2021-06-30 | 65.41% | +51.28 pp |
| Q1 2021 | 2021-03-31 | 74.76% | +30.02 pp |
| Q4 2020 | 2020-12-31 | 28.89% | +58.77 pp |
| Q3 2020 | 2020-09-30 | 66.00% | +19.47 pp |
| Q2 2020 | 2020-06-30 | 14.13% | −64.58 pp |
| Q1 2020 | 2020-03-31 | 44.74% | −22.35 pp |
| Q4 2019 | 2019-12-31 | −29.89% | −66.25 pp |
| Q3 2019 | 2019-09-30 | 46.53% | +31.72 pp |
| Q2 2019 | 2019-06-30 | 78.71% | +20.37 pp |
| Q1 2019 | 2019-03-31 | 67.09% | −4.34 pp |
| Q4 2018 | 2018-12-31 | 36.36% | −17.92 pp |
| Q3 2018 | 2018-09-30 | 14.81% | −51.34 pp |
| Q2 2018 | 2018-06-30 | 58.33% | −7.05 pp |
| Q1 2018 | 2018-03-31 | 71.43% | +2.20 pp |
| Q4 2017 | 2017-12-31 | 54.29% | −21.22 pp |
| Q3 2017 | 2017-09-30 | 66.15% | +10.42 pp |
| Q2 2017 | 2017-06-30 | 65.38% | +0.87 pp |
| Q1 2017 | 2017-03-31 | 69.23% | +16.60 pp |
| Q4 2016 | 2016-12-31 | 75.51% | +11.41 pp |
| Q3 2016 | 2016-09-30 | 55.74% | −19.26 pp |
| Q2 2016 | 2016-06-30 | 64.52% | +2.98 pp |
| Q1 2016 | 2016-03-31 | 52.63% | −12.89 pp |
| Q4 2015 | 2015-12-31 | 64.10% | −4.65 pp |
| Q3 2015 | 2015-09-30 | 75.00% | +115.00 pp |
| Q2 2015 | 2015-06-30 | 61.54% | +0.60 pp |
| Q1 2015 | 2015-03-31 | 65.52% | — |
| Q4 2014 | 2014-12-31 | 68.75% | — |
| Q3 2014 | 2014-09-30 | −40.00% | — |
| Q2 2014 | 2014-06-30 | 60.94% | — |
Over the last five reported fiscal years, ENvue Medical's gross margin decreased from 34.35% to 5.99%, a change of −28.36 percentage points. The latest reported quarter, Q2 2026, shows −111.30%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ENvue Medical filings at SEC.gov ↗